



Tilray's CC Pharma Recognized as a TOP 100 Innovator in Germany

Feb 4, 2026

Award Recognizes CC Pharma as an Innovative Leader and Trusted Partner in the European Pharmaceutical Market

DENSBORN, Germany, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), today announced that [CC Pharma](#), its European pharmaceutical distribution business, has been named a [TOP 100 Innovator in Germany](#), one of the country's most respected and independent recognitions for innovation among small and mid-sized enterprises.

CC Pharma operates a nationwide pharmaceutical distribution network serving more than 13,000 pharmacies across Germany, providing reliable access to a broad portfolio of prescription and over-the-counter medicines. The company also plays a key role in the distribution of medical cannabis in Germany, leveraging its established infrastructure, regulatory expertise, and long-standing relationships within the healthcare system to support patient access in a highly regulated market.

For more than 25 years, the TOP 100 Innovator Award has recognized companies demonstrating exceptional innovative strength, long-term viability, and future-focused business practices. Winners are selected through a rigorous, science-based evaluation that assesses innovation management, forward-looking strategy, and sustainable competitiveness, making the TOP 100 seal a trusted signal to customers, suppliers, financial institutions, media, and prospective employees.

Rajnish Ohri, President, International, Tilray Brands, stated, "This recognition underscores CC Pharma's role as a forward-thinking, reliable partner within Germany's pharmaceutical ecosystem. Innovation is not just about technology, it's about building resilient systems, anticipating market needs, and consistently delivering value to partners and patients. CC Pharma exemplifies this approach, and this award reinforces the strength of our European pharmaceutical platform."

Mathias Bossen, Managing Director of CC Pharma, stated, "We are proud to be recognized as a TOP 100 Innovator in Germany. This award validates the work of our entire team and our focus on continuous improvement, digitalization, and long-term partnerships. It confirms that CC Pharma is well positioned for the future and remains a trusted, innovative partner for customers, suppliers, and stakeholders across the pharmaceutical value chain."

CC Pharma's selection as a TOP 100 Innovator reflects its disciplined innovation strategy, strong regional footprint, and commitment to operational excellence in a highly regulated market. The award also highlights CC Pharma's position as an attractive employer and an important contributor to Germany's healthcare supply chain.

About CC Pharma

CC Pharma is a leading pharmaceutical distributor in Germany, serving pharmacies nationwide with a broad portfolio of branded and generic medicines. As part of Tilray Brands, CC Pharma combines local market expertise with the scale, discipline, and strategic resources of a global organization.

For more information on CC Pharma, visit <https://www.cc-pharma.de/en/>

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.

For more information on Tilray Medical, visit Tilray Medical Europe, [Tilray Medical Canada](#), and [Tilray Medical Australia-New Zealand](#).

About Tilray Brands

Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit [Tilray.com](https://www.tilray.com) and follow @Tilray on all social platforms.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication, and such assumptions may prove to be incorrect. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks

and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward-looking statements in this communication also include statements regarding the Company's market positioning, anticipated ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact:

CC Pharma GmbH – In den Feldern 2 – 54570 Densborn – Germany

Verena Meiers: marketing@cc-pharma.de

Tilray Brands Media: news@tilray.com

Investors: investors@tilray.com